Objective. To assess the rate of sustained virologic response in patients with chronic hepatitis C or virus-associated liver cirrhosis treated with direct-acting antivirals.
Materials and methods. The study was conducted at Minsk City Center for Infectious Hepatology (Minsk City Clinical Hospital for Infectious Diseases). Totally, 253 patients were included in the study.The proportion of patients with advanced stages of fibrosis or cirrhosis was 103 (40.71%).The sustained virologic response rate after the treatment completion and the laboratory changes during the treatment were evaluated.
Results. The treatment with various drug regimens (i.e. study groups) showed the following rates of sustained virologic response on week 24 after the therapy completion: sofosbuvir+daclatasvir±ribavirin — 97.59%, sofosbuvir+ribavirin — 82.35%, sofosbuvir/ledipasvir±ribavirin — 98.08%, ombitasvir/paritaprevir/ ritonavir +dasabuvir±ribavirin — 100%.
Conclusion. Sofosbuvir+ribavirin has shown the least efficacy among all the other treatment regimens (this regimen should not be recommended even for patients with HCV genotype 2).The sofosbuvir-based regimens cause no significant adverse effect on the renal function in patients with no pre-existing kidney disease.Ключевые слова:
Автор(ы): D. E. Danilov, D. V. Litvinchuk, D. A. Vinogradova, A. V. Matveyenko, I. A. Karpov